Carlsmed, Inc. is a commercial-stage medical technology company developing AI-enabled personalized spine surgery solutions. The company's aprevo Technology Platform provides pre-operative planning software and custom interbody implants for lumbar and cervical spine fusion surgeries, designed to address degenerative disc disease and adult spinal deformity. The platform utilizes AI algorithms to generate personalized surgical plans and produces patient-specific interbody implants and single-use surgical instruments. Carlsmed markets its products to hospitals and ambulatory surgical centers in the United States through a direct sales team and independent sales agents. The company received FDA clearance for its lumbar interbody implants in 2020 and 2022, and for its cervical interbody implants in 2024. In December 2025, the company received FDA clearance for its cervical plating system, known as the corra Cervical Plating System, with broader commercialization expected in 2026. The company focuses on improving surgical outcomes and reducing the need for revision surgeries through personalized digital surgical planning and custom anatomical implants.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage carlsmed.com
Sector Healthcare IR page investors.carlsmed.com
Tags
spine surgery, personalized medicine, ai algorithms, interbody implants, surgical planning software, orthopedics, custom medical devices, lumbar fusion, cervical fusion, aprevo, corra Cervical Plating System
Press page carlsmed.com/newsroom

Metrics

Valuation  
Market cap $ 414.923M
Market cap (USD) $ 414.923M
P/E -7.15
PEG —
P/BV 5.48
P/S 8.21
P/OCF -14.32
P/FCF -14.01
Dividend yield —
Turnover / mcap —
Returns  
ROE -30.0%
ROI -25.9%
ROIC -20.1%
Profit margin -58.7%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) Yes
Debt/Equity 20.4%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 44
Quality score -53.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023
Revenue 50.511M 27.165M 13.778M
Net profit -29.634M -24.257M -18.898M
Free cash flow -29.619M -25.646M -17.615M

Figure FY 2025 FY 2024 FY 2023
Share price 12.35 — —
P/FCF -11.09 — —

Filed figures

Figure Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 6.77M 11.4M
↳ YoY growth +67.9%
Lease liabilities (USD) — 1.77M 2.07M
Cash and deposits (USD) 7.22M 40.1M 85.8M
Right-of-use assets (USD) — 1.64M 1.83M
Cash flow detail
Operating cash flow (USD) — -25.5M -29M
Purchases of property, plant and equipment (USD) — -180,000 -642,000
Purchases of intangible assets (USD) — 0.00 -715,000
Change in receivables (cash effect) (USD) — -3.97M -5.01M
Change in inventories (cash effect) (USD) — -1.8M -2.69M
Change in payables (cash effect) (USD) — 297,000 2.32M
Share-based compensation (USD) — 253,000 1.93M
Operating cash flow before change in receivables (USD) — -21.5M -24M
Free cash flow (OCF - PPE - intangibles) (USD) — -25.6M -30.3M
Income detail
Research and development expense (USD) — 14.3M 17M
Total comprehensive income (USD) — -24.3M -29.6M
Comprehensive income to owners (USD) — -24.3M -29.6M
Reported Aug 28, 2025 Feb 25, 2026 Feb 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Third quarter 2026 revenue of $21.6 million, representing 65% growth year-over-year

Full year 2026 revenue guidance raised to $78 million to $80 million

CARLSBAD, CALIFORNIA, NOVEMBER 10, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the third quarter ended September 30, 2026.

“The third quarter represented strong execution against our long-term strategy as we delivered 65% revenue growth and advanced our leadership position in AI-enabled personalized surgery as we grew our surgeon user base by more than 60% over the prior year,” said Mike Cordonnier, Chairman and CEO of Carlsmed. "We broadened our personalized surgery platform, strengthened our leadership team, and secured new inpatient CMS reimbursement for our aprevo® lumbar spine fusion procedure.

Skip to content

Press Release Details

Carlsmed, Inc. to Report Third Quarter 2026 Financial Results on November 10, 2026

Oct 27, 2026

PDF Version

CARLSBAD, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its third quarter 2026 financial results after market close on Tuesday, November 10, 2026. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time.

A live webcast of the conference call will be available in the Events & Presentations section of the Company’s investor website at investors.carlsmed.com. Participants may also join via telephone by registering here. A replay will be archived on the Company’s website following completion of the call.

About Carlsmed

Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.

Investor Relations [email protected]

Media[email protected]

Skip to content

Press Release Details

Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System

Oct 14, 2026

PDF Version

CARLSBAD, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the U.S. commercial launch of its aprevo® Lumbar Bi-lateral Posterior System at the North American Spine Society’s 41st Annual Meeting (NASS) in San Antonio, TX. The launch follows a limited market evaluation that commenced in February 2026, with the first in human procedure completed on February 10, 2026.

“The launch of the Bi-lateral System further expands our proprietary technology platform to enable a direct posterior approach for personalized spine fusion,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “The Bi-lateral System is optimized to support planned three-dimensional correction of the spine with maximal surface area contact.”

“Since its initial release, aprevo® has established itself as a valuable tool in my surgical armamentarium, allowing me to achieve a new level of patient specificity in my procedures,” stated Dr. CJ Kleck of University of Colorado. “I have been impressed with the results achieved and look forward to utilizing the technology when appropriate for my patients.”

“I see great potential in this system for patients who may benefit from a posterior approach,” added Dr. Joshua Bakhsheshian of Mayo Clinic, who will be sharing his clinical experience with aprevo® Bi-lateral at NASS. “Carlsmed’s technology has enabled a greater level of patient specificity in preoperative planning, with the potential to contribute to improved long-term patient outcomes.”

Carlsmed’s Bi-lateral System leverages the Company’s technology platform, which combines proprietary AI-enabled software and clinical intelligence to deliver surgeon-specific three-dimensional surgical plans and patient-specific fusion devices across a broad range of spinal pathologies.

About Carlsmed Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.

Forward-Looking StatementsAny statements in this press release about future expectations, plans and prospects, including statements about the potential of Carlsmed’s products, statements regarding patient outcomes and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including such important factors as are set forth under the caption “Risk Factors” in Carlsmed’s Annual Report on Form 10-K on file with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Carlsmed’s views as of the date of this press release. Carlsmed anticipates that subsequent events and developments will cause its views to change. However, while Carlsmed may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Carlsmed’s views as of any date subsequent to the date of this press release.

Investor Relations [email protected]

Media [email protected]

Prompts

Carlsmed, Inc. (ticker CARL), listed in United States.

ETFs Holding Carlsmed, Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.00% 695 $ 12.058K Nov 16, 2026